These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19110646)

  • 21. Retroviral insertion site analysis in dominant haematopoietic clones.
    Kustikova OS; Modlich U; Fehse B
    Methods Mol Biol; 2009; 506():373-90. PubMed ID: 19110639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toolbox for retrovectorologists.
    Pagès JC; Bru T
    J Gene Med; 2004 Feb; 6 Suppl 1():S67-82. PubMed ID: 14978752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors.
    Bauer G; Dao MA; Case SS; Meyerrose T; Wirthlin L; Zhou P; Wang X; Herrbrich P; Arevalo J; Csik S; Skelton DC; Walker J; Pepper K; Kohn DB; Nolta JA
    Mol Ther; 2008 Jul; 16(7):1308-15. PubMed ID: 18461052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy in retrovirally modified haematopoietic cell therapy.
    Li Z; Modlich U; Baum C
    Best Pract Res Clin Haematol; 2004 Sep; 17(3):493-503. PubMed ID: 15498719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gibbon ape leukemia virus poorly replicates in primary human T lymphocytes: implications for safety testing of primary human T lymphocytes transduced with GALV-pseudotyped vectors.
    Lamers CH; Willemsen RA; van Elzakker PM; Gratama JW; Debets R
    J Immunother; 2009 Apr; 32(3):272-9. PubMed ID: 19242373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of retroviral integration sites by linear amplification-mediated PCR and tracking of individual integration clones in different samples.
    Schmidt M; Schwarzwaelder K; Bartholomae CC; Glimm H; von Kalle C
    Methods Mol Biol; 2009; 506():363-72. PubMed ID: 19110638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insertional mutagenesis in gene therapy and stem cell biology.
    Baum C
    Curr Opin Hematol; 2007 Jul; 14(4):337-42. PubMed ID: 17534158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of recommendations for replication-competent retrovirus testing associated with use of retroviral vectors.
    Wilson CA; Ng TH; Miller AE
    Hum Gene Ther; 1997 May; 8(7):869-74. PubMed ID: 9143913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted gene modification in mouse ES cells using integrase-defective lentiviral vectors.
    Okada Y; Ueshin Y; Hasuwa H; Takumi K; Okabe M; Ikawa M
    Genesis; 2009 Apr; 47(4):217-23. PubMed ID: 19208434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of retroviral vectors for gene transfer into hematopoietic stem cells.
    Holst J; Rasko JE
    Methods Enzymol; 2006; 420():82-100. PubMed ID: 17161695
    [No Abstract]   [Full Text] [Related]  

  • 31. Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients.
    Marcucci KT; Jadlowsky JK; Hwang WT; Suhoski-Davis M; Gonzalez VE; Kulikovskaya I; Gupta M; Lacey SF; Plesa G; Chew A; Melenhorst JJ; Levine BL; June CH
    Mol Ther; 2018 Jan; 26(1):269-279. PubMed ID: 29203150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insertional mutagenesis and clonal dominance: biological and statistical considerations.
    Fehse B; Roeder I
    Gene Ther; 2008 Jan; 15(2):143-53. PubMed ID: 17972922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Release testing of retroviral vectors and gene-modified cells.
    Nordling D; Kaiser A; Reeves L
    Methods Mol Biol; 2009; 506():265-79. PubMed ID: 19110632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retroviral integration site analysis in hematopoietic stem cells.
    Kustikova OS; Baum C; Fehse B
    Methods Mol Biol; 2008; 430():255-67. PubMed ID: 18370305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retroviral vectors: post entry events and genomic alterations.
    Nowrouzi A; Glimm H; von Kalle C; Schmidt M
    Viruses; 2011 May; 3(5):429-55. PubMed ID: 21994741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genome-wide analysis of retroviral DNA integration.
    Bushman F; Lewinski M; Ciuffi A; Barr S; Leipzig J; Hannenhalli S; Hoffmann C
    Nat Rev Microbiol; 2005 Nov; 3(11):848-58. PubMed ID: 16175173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Production of retroviral vectors for clinical use.
    Cornetta K; Reeves L; Cross S
    Methods Mol Biol; 2008; 433():17-32. PubMed ID: 18679615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector.
    Manilla P; Rebello T; Afable C; Lu X; Slepushkin V; Humeau LM; Schonely K; Ni Y; Binder GK; Levine BL; MacGregor RR; June CH; Dropulic B
    Hum Gene Ther; 2005 Jan; 16(1):17-25. PubMed ID: 15703485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retroviral bicistronic vectors.
    Pfützner W
    Drug News Perspect; 2008 Nov; 21(9):473-80. PubMed ID: 19180265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diverse genomic integration of a lentiviral vector developed for the treatment of Wiskott-Aldrich syndrome.
    Mantovani J; Charrier S; Eckenberg R; Saurin W; Danos O; Perea J; Galy A
    J Gene Med; 2009 Aug; 11(8):645-54. PubMed ID: 19455589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.